분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-08-31 03:22:37 , Hit : 695
 UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis

https://endpts.com/fda-ushers-in-a-new-era-in-cancer-treatment-with-game-changing-car-t-approval-for-novartis/?utm_medium=email&utm_campaign=ALERT+FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis&utm_content=ALERT+FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis+CID_b478855548eb40528cf6ab7b72a04479&utm_source=ENDPOINTS+emails&utm_term=FDA+ushers+in+a+new+era+in+cancer+treatment+with+historic+CAR-T+approval+for+Novartis

by John Carroll — on August 30, 2017 11:07 AM EDT


The FDA has approved the world’s first CAR-T therapy, giving a green light to Novartis for Kymriah (tisagenlecleucel) in what regulators themselves describe as an historic event.

The early approval — about a month ahead of the PDUFA date — came through for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia.

Novartis set the price for the one-time treatment at $475,000, right in line with low-end estimates and one that will put pressure on Gilead to rein in its own price for a rival therapy expected to be approved in the near future.

None other than FDA commissioner Scott Gottlieb did the honors in the agency’s statement, noting:


We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer. New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.

A group of biopharma companies have been racing to this breakthrough point. Kite Pharma $KITE, newly bought out in a $12 billion deal by Gilead $GILD, is coming in a close second with its own application for axicel.

Novartis’ investigators registered a game-changing 83% remission rate in its pivotal study.

CAR-T, though, is also associated with severe and potentially deadly side effects, including lethal instances of cytokine release syndrome with some patients dying from brain swelling in separate studies from the Novartis drug.

Regulators noted that they will require special training for anyone involved in delivering this therapy, while expanding the approval of Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening CRS in patients 2 years of age or older. “In clinical trials in patients treated with CAR-T cells,” the FDA reported, “69% of patients had complete resolution of CRS within two weeks following one or two doses of Actemra.”

This therapy, which is made using a patient’s own immune cells, won’t be cheap.

By its own reckoning, the UK’s tough watch dog on drug pricing has said that these drugs would be worth up to $649,000 a year, given the young patients it’s targeting first. Analysts, meanwhile, have pegged the price at anywhere from $400,000 to $750,000.

In a call with analysts, Novartis execs said it would keep the price well below the high end, setting the cost at $475,000 for a drug that will be available in 20 centers within one month, and 35 soon after.

In a statement the company said it “is collaborating with CMS to make an outcomes-based approach available to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month. Future potential indications would be reviewed for the most relevant outcomes-based approach.”

Said Joseph Jimenez, CEO of Novartis:


Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care.

This approval marks a major shift in oncology, with a truly revolutionary approach to treating cancer. That hasn’t escaped the notice of big players and small, with a host of developers looking to do much better, more safely, with new drugs in the pipeline.

It’s a big day in the biotech world, but it’s just the official start date for a new era.







1227   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 569
1226   Alcoholism Gene Therapy Shows Promise  이성욱 2017/09/20 582
1225   CRISPR Used in Human Embryos to Probe Gene Function  이성욱 2017/09/22 583
1224   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 589
1223   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 591
1222   Nature Methods retracts CRISPR study  이성욱 2018/04/10 600
1221   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 605
1220   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 609
1219   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 614
1218   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 640
1217   DNA Construction  이성욱 2017/09/15 660
1216   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 665
1215   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 671
1214   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 689
1213   First CAR T-Cell Therapy Approved in U.S.  이성욱 2017/09/01 691
  UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 695
1211   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 701
1210   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 701
1209   Mammalian Immunity: What’s RNAi Got to Do with It?  이성욱 2017/07/25 704
1208   코오롱 인보사허가  이성욱 2017/07/12 706

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN